ProBioGen’s GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals
Berlin (ots/PRNewswire) - Bispecific Antibody for Cancer Treatment Optimized by GlymaxX® Technology
ProBioGen AG, a premier service & technology provider for complex therapeutic antibodies and glycoproteins, announced today that the company achieved an undisclosed milestone payment from Merus N.V. (Nasdaq: MRUS) based on Merus' grant of an exclusive license to Hangzhou, Zhejiang Province based Betta Pharmaceuticals Co., Ltd to develop and commercialize in China Merus' novel MCLA-129, Biclonics® bispecific antibody!-->…